Investing In China: Views From Windhover's PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
It's common wisdom within the halls of Big Pharma to look East--especially to China--for future revenue growth as increasing regulatory oversight and reimbursement hurdles in the U.S. and Europe create commercial challenges
You may also be interested in...
At PharmAsia Summit, VCs Discuss Financing Innovation in Asia
SAN FRANCISCO - In spite of the generally gloomy forecasts for the venture industry, emerging markets in Asia reveal selective opportunities that could bring strong returns for VCs
At PharmAsia Summit, VCs Discuss Financing Innovation in Asia
SAN FRANCISCO - In spite of the generally gloomy forecasts for the venture industry, emerging markets in Asia reveal selective opportunities that could bring strong returns for VCs
Roche Forms New Clinical Research Hub In Singapore To Accelerate Progress In Personalized Medicine
PERTH, Australia - Roche announced Jan. 28 a major strategic alliance with Singapore's leading scientific and medical institutions to establish a new translational research hub in Singapore